Abstract: A method is described for the diagnosis of rosacea. The method can include a step of measuring the expression of at least one peptide from the galanin family in a sample of biological fluid from a patient. Also described, is a related diagnostic kit.

Abstract: The use of a CGRP receptor antagonist compound of formula (I) for topical application is described for treating and/or preventing skin inflammatory pathologies with a neurogenic component. More specifically, use of a CGRP receptor antagonist compound of formula (I) is described for topical application for treating and/or preventing rosacea, especially type I rosacea, atopic dermatitis, psoriasis and/or acne.

Abstract: Described herein is a method of using a topical, pharmaceutical composition, particularly a dermatological composition, comprising naratriptan to treat rosacea and in particular erythematotelangiectatic rosacea.

Abstract: Checking the layout integrity includes the steps of receiving inputs defining a plurality of devices for a layout, generating a signature for each device in the layout, when created, from one or more parameters of the device, storing the generated signatures with the layout, receiving the stored layout and signatures, regenerating each signature for each device in the stored layout, and comparing each regenerated signature with the corresponding stored signature.

Abstract: Described herein is a method of using a topical, pharmaceutical composition, particularly a dermatological composition, comprising naratriptan to treat rosacea and in particular erythematotelangiectatic rosacea.

Abstract: A method is described for treating and/or preventing acne scars wherein an effective amount of a composition including a fixed combination of adapalene or a salt thereof and benzoyl peroxide is administrated to a patient in need thereof. Also described, is a composition that includes a fixed combination of adapalene or a salt thereof and benzoyl peroxide for treating and/or preventing acne scars.

Abstract: Compounds or salts thereof are described that correspond to general formula (I) below: Also described, are pharmaceutical and cosmetic compositions that include these compounds. Methods of using these compounds and compositions for the treatment of pathological conditions are also described.

Abstract: Checking the layout integrity includes the steps of receiving inputs defining a plurality of devices for a layout, generating a signature for each device in the layout, when created, from one or more parameters of the device, storing the generated signatures with the layout, receiving the stored layout and signatures, regenerating each signature for each device in the stored layout, and comparing each regenerated signature with the corresponding stored signature.

Abstract: Compounds or salts thereof are described that correspond to general formula (I) below: Also described, are pharmaceutical and cosmetic compositions that include these compounds. Methods of using these compounds and compositions for the treatment of pathological conditions are also described.

Abstract: A method is described for the diagnosis of rosacea. The method can include a step of measuring the expression of at least one peptide from the galanin family in a sample of biological fluid from a patient. Also described, is a related diagnostic kit.

Abstract: Novel biaromatic compounds that modulate peroxisome proliferator-activator receptors, known as PPAR, having the formula (I): are formulated into pharmaceutical compositions useful in human or veterinary medicine, or alternatively, in cosmetic compositions.

Abstract: Markers for rosacea among the chemokines and cytokines and their receptors, selected from interleukin 8 (IL-8), CXCL1, CXCL2, CXCL3 and CXCL5, the CXCR1 receptor and the CXCR2 receptor are described. Also described, is a method for the diagnosis of rosacea.

Abstract: An in vitro or in vivo method for screening for candidate compounds for the preventive or curative treatment of acne, of seborrhoeic dermatitis or of skin disorders associated with hyperseborrhoea, includes determining the ability of a compound to modulate the expression or the activity of the phosphatidylcholine transfer protein (PCTP), and also utilizes modulators of the expression or of the activity of this protein, for the treatment of acne, of seborrhoeic dermatitis or of skin disorders associated with hyperseborrhoea; methods for the in vitro diagnosis of or in vitro prognosis for these pathologies are also featured.

Abstract: An in vitro or in vivo method for screening for candidate compounds for the preventive or curative treatment of acne, of seborrhoeic dermatitis or of skin disorders associated with hyperseborrhoea, includes determining the ability of a compound to modulate the expression or the activity of isovaleryl-coenzyme A dehydrogenase (IVD), and also utilizes modulators of the expression or of the activity of this enzyme, for the treatment of acne, of seborrhoeic dermatitis or of skin disorders associated with hyperseborrhoea; methods for the in vitro diagnosis of or in vitro prognosis for these pathologies are also featured.

Abstract: An in vitro or in vivo method for screening for candidate compounds for the preventive or curative treatment of acne, of seborrhoeic dermatitis or of skin disorders associated with hyperseborrhoea, includes determining the ability of a compound to modulate the expression or the activity of monoglyceride lipase (MGLL), and also utilizes modulators of the expression or of the activity of this enzyme, for the treatment of acne, of seborrhoeic dermatitis or of skin disorders associated with hyperseborrhoea; methods for the in vitro diagnosis of or in vitro prognosis for these pathologies are also featured.

Abstract: Modulators of specific PACAP receptors are useful for treating inflammatory skin diseases having a neurogenic component, and more particularly rosacea and/or facial erythema, compositions containing these and screening methods are described for identifying PACAP signaling pathway modulators.

Abstract: Novel compounds having the general formula (I) below: are useful in a wide variety of applications in human or veterinary medicine (in dermatology, and also in the fields of cardiovascular diseases, immune diseases and/or diseases associated with lipid metabolism), or, alternatively are formulated into cosmetic compositions.

Abstract: An in vitro or in vivo method for screening for candidate compounds for the preventive or curative treatment of acne, of seborrhoeic dermatitis or of skin disorders associated with hyperseborrhoea, includes determining the ability of a compound to modulate the expression or the activity of the CYP2B15 and/or glycerol-3-phosphate dehydrogenase 1 (GPD1) proteins.

Abstract: An in vitro or in vivo method for screening for candidate compounds for the preventive or curative treatment of acne, of seborrhoeic dermatitis or of skin disorders associated with hyperseborrhoea, includes determining the ability of a compound to modulate the expression or the activity of the CIDEA protein, and also utilizes modulators of the expression or of the activity of this protein, for the treatment of acne, of seborrhoeic dermatitis or of skin disorders associated with hyperseborrhoea; methods for the in vitro diagnosis of or in vitro prognosis for these pathologies are also featured.

Abstract: Novel biaromatic compounds having the following structural formula (I): are formulated into pharmaceutical compositions suited for administration in human or veterinary medicine, in particular in dermatology as well as in the fields of cardiovascular diseases, immune diseases and/or diseases related to the metabolism of lipids, or, alternatively, into cosmetic compositions.